Bristol-Myers Squibb Company BMY
Verdict: Sell. Fair value $50.83 against a price of $53.06 on 5 Jan 2026, 4% below the price.
In plain words
The case for: Wide competitive moat provides durability. Market leadership enables pricing power. Industry tailwinds with growing market.
The case against: Intense competitive pressure could compress margins. 2024 Net Income was -$8.95B (loss) while Operating Cash Flow was +$15.19B. This $24B spread.... Net Income swung from +$8.03B in 2023 to -$8.95B in 2024, a decline of over $16B, despite Revenue....
Main risks
- Significant deterioration in GAAP profitability (Net Loss of $8.95B) eroding shareholder equity
- High leverage ratios: Debt-to-Equity > 3.0x and Net Debt/EBITDA > 3.0x indicate stretched balance sheet
- Negative ROIIC (-1.5%) suggests recent capital deployment (acquisitions/R&D) has not yet yielded incremental EBIT growth
- Near-term debt maturity concerns
- 2024 Net Income was -$8.95B (loss) while Operating Cash Flow was +$15.19B. This $24B spread...
- Intense competitive environment